Diabetic Retinopathy and Current Treatment Challenges
Diabetic Retinopathy (DR) is a condition in which the delicate blood vessels of the retina are damaged by diabetes, leading to vision loss. When blood glucose levels remain elevated over a prolonged period, these retinal blood vessels can become occluded or leak. This deprives the retina of oxygen, preventing it from maintaining normal visual function.
As the disease progresses, abnormal new blood vessels (neovascularization) grow on the retina, leading to hemorrhage and retinal detachment, and can result in blindness. Currently, treatment for diabetic retinopathy primarily includes the following symptomatic therapies:
- Kontrol gula darah dan pemantauan:The first thing is to manage blood sugar levels well. However, unfortunately, even with proper blood sugar management, there are cases where retinopathy continues to progress.
- Fotokoagulasi laser:Laser is applied to the retina to burn areas that require high oxygen, inhibiting the development of new blood vessels. This is an effective treatment for preserving vision, but does not fundamentally repair retinal damage.
- Injeksi intravitreal obat anti-VEGF:To suppress edema (swelling) occurring in the retina and abnormal blood vessels, drugs that inhibit vascular endothelial growth factor (VEGF) are periodically injected into the eyeball. This suppresses the progression of lesions in many patients, but requires injections approximately once a month, which is an economic and physical burden...
- Operasi vitreous:When vitreous hemorrhage or retinal detachment occurs, accompanied by abnormal blood vessel growth, vitreous surgery removes the bleeding within the eye and scar tissue. This is a surgery that requires advanced medical equipment and expertise, but it serves as a last resort to halt the progressing lesion.
However, all currently available treatment modalities aim to slow or halt disease progression, rather than offering a definitive cure for diabetic retinopathy itself. Indeed, even with ongoing therapeutic intervention, it remains challenging to entirely avert future retinal damage and subsequent visual impairment.
For instance, reports indicate that even after 2 years of continuous anti-VEGF therapy, only approximately 30% of patients experienced significant visual improvement, highlighting the limitations of treatment efficacy. Furthermore, the demanding nature of routine visits and injections often makes it challenging for many patients to adhere to treatment.
Thus, while current treatments can suppress the progression of retinopathy, restoring damaged retinas to their original state remains challenging, thereby increasing expectations for novel therapeutic modalities.
Prolonged hyperglycemia damages blood vessels throughout the body. This is analogous to a road cracked by years of rain and wind, rendering it difficult to traverse. Healthy arteries are like wide thoroughfares where blood flows smoothly. However, when atherosclerosis occurs, plaque, such as cholesterol deposits, accumulates within the blood vessels, causing the pathway to narrow. Consequently, blood flow deteriorates, and essential oxygen and nutrients cannot be delivered.
In diabetic retinopathy, this phenomenon occurs in the microvasculature of the retina at the back of the eye. When these blood vessels become occluded and blood flow deteriorates, retinal cells become oxygen-deprived and damaged. Current treatment primarily consists of symptomatic therapy to suppress "new abnormal blood vessel proliferation" (neovascularization) or "hemorrhage" that arise as a result of this damage. In other words, the focus is on addressing the immediate issues.
Ultimately, the goal is to repair damaged blood vessels and the retinal tissue itself. As such a fundamental approach, stem cell therapy has garnered significant attention in recent years. Stem cells possess the ability to aid in repairing damaged tissue and promote blood vessel regeneration, and are expected to remodel the retinal environment.
Emerging Possibilities in Stem Cell Therapy and Regenerative Medicine for Diabetic Retinopathy
In light of the advancements in regenerative medicine in recent years, novel therapeutic methods utilizing stem cells are being explored for diabetic retinopathy. Stem cells are specialized cells possessing the capacity to differentiate into various cell types and the ability to repair tissues, effectively serving as the body's intrinsic reserves.
Administering stem cells to the patient facilitates the regeneration and repair of damaged retinal tissue, with the aim of restoring vision and resolving lesions that were previously challenging to treat with conventional therapies.
Indeed, research into stem cell therapy for diabetic retinopathy is ongoing worldwide. Preclinical animal studies have demonstrated that stem cells can slow the progression of retinopathy and alleviate symptoms. For instance, studies have involved transplanting stem cells into the retinas of blind mice to restore visual neural cell function. Additionally, research has shown that administering stem cell-derived factors to animals under hyperglycemic conditions can suppress retinal inflammation.
Given the success of this pre-clinical research, stem cell therapy is showing great promise as a new treatment option for diabetic retinopathy.
There are several types of stem cells. Stem cells derived from the patient's bone marrow and adipose tissue, as well as artificially created induced pluripotent stem cells (iPS cells), are currently under investigation. Among these, particular attention is being paid to umbilical cord-derived mesenchymal stem cells (Wharton's Jelly-derived MSCs: WJ-MSCs), which are extracted from the Wharton's jelly portion of the umbilical cord.
WJ-MSCs, derived from fetal tissue, are characterized by their youthful properties and high proliferative capacity. Furthermore, the umbilical cord, which is typically discarded post-natally, can be safely collected without imposing a burden on the infant or the pregnant mother, and without ethical concerns. Moreover, WJ-MSCs are known to exhibit low immunogenicity (high immune tolerance), permitting the use of allogeneic cells. Therefore, WJ-MSCs are considered strong candidates for stem cell therapy for diabetic retinopathy.
Leveraging the power of stem cells and regenerative medicine, it is possible to repair damaged retinal tissue itself and fundamentally treat vision loss caused by diabetic retinopathy. This represents a unique advantage of regenerative medicine, absent in current symptomatic therapies, and holds significant promise for patients.
Mechanism of Action of Stem Cell Therapy for Diabetic Retinopathy
Inhibition of Inflammation and Pathological Angiogenesis (Immunomodulatory)
In diabetic retinopathy, chronic inflammatory reactions develop in the retina due to hyperglycemic stress, leading to extensive damage. Stem cells secrete a variety of factors that mitigate inflammation, thereby modulating dysfunctional immune responses, stabilizing the retinal microenvironment, and inhibiting the progression of pathological alterations.
Furthermore, abnormal blood vessels (neovascularization) that develop in association with inflammation are also suppressed by factors secreted by stem cells. In this manner, stem cells stabilize the retinal microenvironment and inhibit the progression of pathological alterations.
Repairing Blood Vessels and Promoting Normal Blood Flow
Stem cells possess the ability to repair damaged tissue. In diabetic retinopathy, compromised capillaries and vascular networks present a significant challenge. However, stem cells can differentiate into cells that facilitate vascular repair (such as pericytes, which provide support around blood vessels) and have been reported to achieve this.
Indeed, in animal experiments, it has been demonstrated that when stem cells are administered into the eye, both retinal capillary density and blood flow increase. This ensures that sufficient oxygen and nutrients reach the retina, allowing for the repair of tissue damage and ischemic conditions.
Protecting and Regenerating Retinal Nerve Cells
The retina is a component of the nervous tissue, containing crucial neuronal cells such as photoreceptor cells and ganglion cells. Stem cells secrete numerous neurotrophic factors (such as neurotrophins) that provide neuroprotection and enhance the survival of injured retinal neurons.
For example, in a model of mouse retinal nerve damage, when human WJ-MSCs were transplanted into the vitreous, the action of anti-inflammatory and neurotrophic factors secreted by the stem cells resulted in a significant decrease in retinal ganglion cell death...
In this manner, stem cells protect retinal neurons, and by promoting their differentiation into new cells as required, they are believed to facilitate the regeneration of retinal tissue. Notably, the collection of substances secreted by stem cells is termed the "secretome," which encompasses various factors, including exosomes (small vesicles approximately 50-150nm in diameter released by cells).
This secretome is pivotal to the therapeutic effects, and it is understood that stem cells heal the retina not merely by differentiating, but also by secreting beneficial factors. For example, in a study where stem cell-derived exosomes were administered to the retina of a diabetic model, a specific signaling pathway (the Wnt/β-catenin pathway), which was dysregulated in the retina, was suppressed. This suppression consequently led to a reduction in oxidative stress, inflammation, and the progression of neovascularization. These results suggest the possibility that stem cell-derived factors alone can adequately inhibit retinopathies.
Summary of Mechanism of Action
The therapeutic effect of stem cell therapy on the retina is not attributed to a single mechanism, but rather to the synergistic action of multiple processes. The primary mechanisms are as follows:
- Suppressing inflammation and abnormal vascular proliferation (with immunomodulatory effects)
- Restoring blood vessels and promoting normal blood flow.
- Protecting and regenerating retinal nerve cells
Through such interventions, stem cell therapy possesses the potential to halt the progression of diabetic retinopathy and, furthermore, restore the structure and function of the damaged retina.
Evidence of Effectiveness of Stem Cell Therapy for Diabetic Retinopathy
Findings from Pre-clinical Research (Animal Experiments):
Numerous studies utilizing animal models of diabetic retinopathy have reported promising results from stem cell therapy. For instance, in an experiment where exosomes extracted from bone marrow-derived mesenchymal stem cells were administered to diabetic mice, retinal inflammation and abnormal blood vessel proliferation were suppressed, and symptoms of retinopathy caused by...
This supports the aforementioned "secretome," indicating that the improvement in retinopathy occurs not through the cells themselves but via factors secreted by the stem cells. Furthermore, in other studies, bone marrow-derived CD34+ stem cells (possessing the ability to regenerate blood and blood vessels) administered to diabetic retinas led to the preservation of retinal vascular tissue. In other words, the use of stem cells facilitates the maintenance of retinal vascular tissue and can ameliorate blood flow deficiencies caused by diabetes.
Findings from Clinical Research (Human Verification)
The therapeutic effects of stem cells are increasingly being reported in clinical studies involving human patients. For instance, in a clinical trial conducted in China, intravenous infusion of umbilical cord-derived mesenchymal stem cells (WJ-MSCs) was administered to 61 patients with type 2 diabetes, with follow-up extended for 3 years (PubMed ID: 27588104).
The findings revealed that the group receiving stem cell injections exhibited a reduced incidence of complications, particularly diabetic retinopathy, compared to the untreated control group. Indeed, at the 3-year follow-up, the incidence of new-onset retinopathy was 16.1% in the stem cell therapy group compared to 26.7% in the control group, a statistically significant difference. This suggests the potential for stem cell therapy to prevent and inhibit the progression of retinopathy.
Furthermore, in this trial, improvements in blood sugar control indicators (HbA1c and blood peptide levels) were also observed, suggesting the possibility that stem cell therapy improves whole-body glucose metabolism and indirectly alleviates retinopathy.
Importantly, these are significant findings demonstrating that stem cell therapy can have beneficial effects on the course of diabetic retinopathy in humans, and the prospects for larger clinical trials are further enhanced. It is noteworthy that no adverse effects were observed with this treatment.
Currently, clinical trials for stem cell therapy for diabetic retinopathy are underway in various countries worldwide, and it is anticipated that more definitive evidence will accumulate over the next few years. Consequently, the day when stem cell therapy can be employed in clinical practice is fast approaching.
Safety and Side Effects of Stem Cell Therapy for Diabetic Retinopathy
When evaluating novel therapeutic approaches, safety is of paramount importance. However, for stem cell therapy, an overall favorable safety profile has been reported in studies to date.
Notably, mesenchymal stem cell (MSC) therapy is recognized for its superior safety profile compared to other cell therapies. MSCs exhibit a low risk of tumorigenicity and are also known to rarely induce immune rejection, thereby allowing for the safe administration of allogeneic cells.
Indeed, in the aforementioned clinical study, no serious adverse events were observed in patients administered stem cell infusions, and no significant difference in safety was confirmed when compared to the saline control group.
Thus, within the currently reported scope, stem cell therapy can impose a substantial burden on patients and is regarded as a highly safe treatment. Nevertheless, stem cell therapy for diabetic retinopathy remains in the research phase, and efforts are underway to safely achieve maximum efficacy. For example, rather than directly introducing stem cells into the eye, an approach employing beneficial components of stem cells (such as stem cell culture supernatant with exosomes)...
This method avoids the direct use of cells, thereby circumventing the risks of immune responses or the undesired proliferation of membrane-forming cells, and is thus expected to be clinically safer. Indeed, in animal studies, while direct transplantation of stem cells into the eye sometimes resulted in temporary inflammatory reactions, injecting only stem cell culture supernatant (conditioned medium) prevented retinal inflammation. Instead, neural cells were protected, and visual function improved. These findings have garnered attention as a novel method to achieve both "safety" and "effectiveness" in stem cell therapy.
From all this, it can be concluded that stem cell therapy presents fewer side effects compared to conventional treatment methods and can be considered with confidence. However, as it is a novel treatment, it is essential to receive thorough explanations and ensure full understanding before undergoing the procedure. With further research, more safety data will be accumulated, and stem cell therapy for diabetic retinopathy is expected to become a safer and more established medical treatment in the future.
Conclusion
Stem cell therapy for diabetic retinopathy is a cutting-edge medical treatment, replete with significant potential and great promise, as demonstrated by ongoing research. Retinal damage, previously considered irreversible, is being ameliorated, making the prospect of preserving vision more tangible.
Of course, clinical application requires further verification, but clinical trials are being vigorously conducted nationally and internationally, and it is hoped that its practical application will be within sight in the next few years. For patients and their families, stem cell therapy can beA new light that curbs the fear of blindness" dan solusi regeneratif sejati.
For those concerned about the treatment of diabetic retinopathy and individuals interested in novel regenerative medicine, please consult a specialized ophthalmic care facility. While stem cell therapy is not currently covered by insurance, updated information regarding participation in clinical trials is available. We recommend a thorough discussion with a specialist physician regarding treatment options based on the latest knowledge.
We also offer consultations on advanced treatments of this kind at any time. We hope that the benefits of new therapies will soon reach those suffering from diabetic retinopathy.